← board
ANTX
AN2 Therapeutics, Incdistress 4/10 · elevated risk$4.76-3%today-13% from 52w high
Lead: Chagas disease
Revenue
pre-revenue
Liquidity
$53M
Runway
1.7 yrs
Shares 1y
+32%
Price & events
+293.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
+1.9%
1W
-4.4%
1M
+11.2%
3M
+306.8%
6M
+317.5%
1Y
+73.1%
2Y
—
5Y
-69.1%
All
Overview
- Market Cap
- $171.44M
- Volume
- 3.96K
- 52 Week Range
- $1.03 – $5.46
- Total Shares
- 36.02M
- Float Shares
- 19.98M
- Short %
- 6.40%
- % Held by Insiders
- 18.99%
- % Held by Institutions
- 70.59%
- RVOL
- 0.01x
- Beta
- -0.99
Pipeline stages · 1 programs
AN2-502998
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03-14 | Phase 1 | AN2-502998 | Healthy Volunteers | 72 | completed |
Catalyst news & presentations · 8
- 2027Guided 40%trial initiationsecondaryPhase 3Epetraborole · Phase 3 trial initiationSEC 8-K
- 2027Guided 40%readoutPhase 2AN2-502998 · Phase 2 data readoutSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 2AN2-502998 · Phase 2 trial initiationSEC 8-K
- YE 2026Guided 40%readoutPhase 2Epetraborole · Phase 2 topline data readoutSEC 8-K
- 2H25trial initiationsecondaryPhase 2epetraborole · Phase 2 study planned to reduce mortalitySEC 8-K
- 2H/2025trial initiationsecondaryPhase 1AN2-502998 · Phase 1 trial startup completionSEC 8-K
- 2Q25readoutepetraborole · Topline data for standard-of-care melioidosis observational trial expectedSEC 8-K
- 2024-08-08trial discontinuedepetraborole · EBO-301 Phase 2/3 study terminated due to efficacy resultsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-07-20GuggenheimBuy
- 2026-05-14Leerink PartnersMarket Perform → Outperform
- 2025-05-05JMP SecuritiesMarket Outperform
- 2025-03-26Citizens Capital MarketsMarket Outperform
- 2025-02-25Citizens Capital MarketsMarket Outperform
- 2025-02-03JMP SecuritiesMarket Outperform
Competitors — Chagas disease
- NVSEFNOVARTIS AG$292.0B · D3
Recent news
- 2026-07-21ANTX Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
- 2026-07-20ANTX Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
- 2026-07-20ANTX Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
- 2026-07-19ANTX Options Volatility — NASDAQ:ANTX - TradingView
- 2026-07-18ANTX Options Chain — NASDAQ:ANTX - TradingView
- 2026-07-14Price to book forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX - TradingView
- 2026-07-10An2 therapeutics COO Joshua Eizen sells $24,802 in stock By Investing.com - Investing.com South Africa
- 2026-07-10AN2 Therapeutics (ANTX) director Aziz Kabeer granted 2,852 shares as fees - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.